The World is Running Out of Effective Antibiotics
In the global race against antimicrobial resistance (AMR) and related
healthcare-associated infections (HAIs), we provide diagnostic solutions
that quickly and accurately identify pathogens to enable the right
isolation and treatment before it's too late.
Join us in the race - MORE results, LESS spread.
True Scale of the AMR Threat
By the year 2050, it is estimated that 10 million people will die annually because of drug-resistant infections.1 Following recently published data in the landmark Lancet GRAM report, we know we are now far closer to this figure than ever realised.2
What is the Silent AMR Pandemic?
The burden of AMR is comparable to that of HIV, TB, and Influenza combined. Video courtesy of the ECDC.
What is the Silent AMR Pandemic?
The burden of AMR is comparable to that of HIV, TB, and Influenza combined. Video courtesy of the ECDC.
COVID-19: AMR Legacy
The COVID-19 pandemic has elevated concerns over AMR and antibiotic-associated adverse events, with surges in antibiotic prescribing, hospitalizations, and drug-resistant bacterial transmissions.6,7
COVID-19 hospital-admitted patients with a secondary bacterial infection.6
COVID-19 hospital-admitted patients who received antibiotics.6
COVID-19 ICU-admitted patients who received antibiotics.8
Future Preparedness
Throughout the COVID-19 pandemic, PCR testing emerged as the superior assay format in terms of accuracy and sensitivity, forming the backbone of nationwide screening regimens.9
Most hospital laboratories now have the capability, awareness, and even the infrastructure to carry out molecular testing, so that shifting from culture- to molecular-based workflows to accelerate turnaround times is more feasible than ever before.
Outbreak Risks
Superbug outbreaks and AMR pose one of the greatest challenges to the healthcare systems, and national elective recovery plans. With the right test, quickly and accurately identify pathogens in under one hour* to enable the right isolation and treatment, keeping wards open, reducing hospital costs, and stopping the spread of resistance.
Cost breakdown from a single outbreak of a rapidly spreading superbug, carbapenemase-producing Enterobacterales (CPE), which exceeded €1,000,000 over 10 months.10
Fight AMR & Superbugs with Fast & Accurate PCR in ~1 Hour*
On-demand identification with the GeneXpert® system's fast PCR Xpert® tests help healthcare professionals reduce onward transmission of resistant bacteria throughout the patient pathway and optimize appropriate therapy management, helping prevent the spread of pathogens and resistance.
Testing in 3 Easy Steps: Sample-In, Answer-Out Technology
1
Insert swab into sample reagent vial and break
2
Transfer sample to cartridge
3
Insert cartridge and start test
Refer to the Cepheid test’s package insert for full details of supported sample types and specimen collection methods
Product Resources
Dr. Fred Tenover: Carbapenemases & Xpert® Carba-R
Dr. Fred Tenover discusses the challenges and solutions to managing the growing threat of CPE, including Xpert® Carba-R, a versatile test that can be used as a surveillance screening test for infection control, an antibiotic resistance test for carbapenemases, and an antimicrobial stewardship tool.
Dr. Fred Tenover: Carbapenemases & Xpert® Carba-R
Dr. Fred Tenover discusses the challenges and solutions to managing the growing threat of CPE, including Xpert® Carba-R, a versatile test that can be used as a surveillance screening test for infection control, an antibiotic resistance test for carbapenemases, and an antimicrobial stewardship tool.
Related Videos
AMR & Carbapenemases
In this short film produced for Cepheid by BBC StoryWorks Commercial Productions and presented by MedTech Europe, Prof. José Artur Paiva (Director, Intensive Care Medicine Service, CHUSJ, Portugal) discusses the important role of fast PCR testing in fighting the growing threat of AMR and CPE.
Carbapenemases
Dr. Tim Neal, Infection Control Doctor at Liverpool Clinical Laboratories, details how fast molecular diagnostic solutions are critical to staying ahead of the emerging threat of CPE.
Carbapenemases
Dr. Thierry Nass, Co-Director of the French National Reference Center for Antibiotic Resistance, details the increasing global threat of CPE, and growing role of fast molecular testing to identify and limit the spread of resistance.
PCR Tools to Fight AMR
Xpert® Carba-R
Xpert® C. difficile BT
Xpert® vanA/vanB
Xpert® MRSA NxG
Xpert® SA Nasal Complete
Xpert® MTB/RIF Ultra
References
CE-IVD In Vitro Diagnostic Medical Device. May not be available
in all countries.
* Turnaround times vary by test. See individual Product Inserts for
specific turnaround times.
^ For positive MRSA results with early assay termination. Otherwise, full
runtime is 70 minutes.
# For positive Norovirus results with early assay termination. Otherwise,
full runtime is 90 minutes.
- World Healt Organization (WHO). 2019. New report calls for urgent action to avert antimicrobial resistance crisish. Accessed March 2022. https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis
- Murray C, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb;399(10325):629-655
- WHO. 2017. The World is Running Out of Antibiotics, WHO Report Confirms. Accessed Sep 2023. https://www.who.int/news/item/20-09-2017-the-world-is-running-out-of-antibiotics-who-report-confirms
- ECDC. 2019. Antimicrobial Resistance: Tackling the Burden in the European Union. Accessed Feb 2023. https://www.oecd.org/health/health-systems/AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf
- MedTech Europe. 2014. Healthcare-Associated Infections Brochure. Accessed Feb 2021. https://www.medtecheurope.org/resource-library/hai-brochure/
- Langford B, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
- Belvisi V, et al. Impact of severe acute respiratory syndrome coro navirus-2 (SARS CoV-2) pandemic on carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) prevention and control program: convergent or divergent action? J Hosp Infect. 2020 Dec;109:29-31
- Pritchard M, et al. International Severe Acute Respiratory and Emerging Infections Consortium, COVID-19 Report: 8 June 2020. medRxiv. Accessed Feb 2021. https://www.researchgate.net/publication/343217999_ISARIC_COVID-19_Clinical_Data_Report_8_June_2020
- Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Accessed November 2022. https://apps.who.int/iris/handle/10665/331501
- Otter J, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. CMI. 2016 Oct;23(3):188-196.